Neurocrine's schizophrenia drug meets main goal in mid-stage study
28/08/2024 12:05
Aug 28 (Reuters) -
Neurocrine Biosciences NBIX.O said on Wednesday its
experimental drug to treat adults with schizophrenia met the
main goal in a mid-stage study.
(Reporting by Mariam Sunny in Bengaluru; Editing by Sriraj
Kalluvila)
((Mariam.ESunny@thomsonreuters.com;))
Recent news on Neurocrine Biosciences
See all newsBrief: Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating Nbi-'567 In Adults With Alzheimer's Disease
Nxera Pharma's Partner Neurocrine Biosciences Receives Ind Acceptance From FDA For Phase 2 Study Of Nbi-1117567 For Alzheimer's Cognition
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Prader-Willi groups cite deaths tied to Neurocrine's genetic disorder drug, shares fall